Kaufman, B. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J. Clin. Oncol. 33, 244\u2013250 (2015).<\/p>\n
Article<\/a>\u00a0 Mirza, M. R. et al. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16\/NOVA trial. Gynecol. Oncol. 159, 442\u2013448 (2020).<\/p>\n Article<\/a>\u00a0 Coleman, R. L. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 1949\u20131961 (2017).<\/p>\n Article<\/a>\u00a0 Kristeleit, R. et al. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1\/2-Mutated Ovarian Carcinoma or Other Solid Tumors. Clin. Cancer Res. 23, 4095\u20134106 (2017).<\/p>\n Article<\/a>\u00a0 Swisher, E. M. et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 18, 75\u201387 (2017).<\/p>\n Article<\/a>\u00a0 Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).<\/p>\n Article<\/a>\u00a0 Laspata, N. et al. PARP1 associates with R-loops to promote their resolution and genome stability. Nucleic Acids Res. 51, 2215\u20132237 (2023).<\/p>\n Article<\/a>\u00a0 Murai, J. et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 72, 5588\u20135599 (2012).<\/p>\n Article<\/a>\u00a0 Ribeiro, J. et al. Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells. Nucleic Acids Res. 53, gkaf1398 (2025).<\/p>\n Ying, S., Hamdy, F. C. & Helleday, T. Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. Cancer Res 72, 2814\u20132821 (2012).<\/p>\n Article<\/a>\u00a0 Panzarino, N. J. et al. Replication gaps underlie BRCA deficiency and therapy response. Cancer Res. 81, 1388\u20131397 (2021).<\/p>\n Article<\/a>\u00a0 Petropoulos, M. et al. Transcription-replication conflicts underlie sensitivity to PARP inhibitors. Nature 628, 433\u2013441 (2024).<\/p>\n Article<\/a>\u00a0 Taylor, R. C., Cullen, S. P. & Martin, S. J. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 9, 231\u2013241 (2008).<\/p>\n Article<\/a>\u00a0 Yuan, J. & Ofengeim, D. A guide to cell death pathways. Nat. Rev. Mol. Cell Biol. 25, 379\u2013395 (2024).<\/p>\n Article<\/a>\u00a0 Newton, K., Strasser, A., Kayagaki, N. & Dixit, V. M. Cell death. Cell 187, 235\u2013256 (2024).<\/p>\n Article<\/a>\u00a0 Croce, C. M. et al. The BCL-2 protein family: from discovery to drug development. Cell Death Differ. 32, 1369\u20131381 (2025).<\/p>\n Article<\/a>\u00a0 Fleury, H. et al. Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat. Commun. 10, 2556 (2019).<\/p>\n Article<\/a>\u00a0 Wyld, L. et al. Senescence and cancer: a review of clinical implications of senescence and senotherapies. Cancers (Basel) 12, 2134 (2020).<\/p>\n de Magalhaes, J. P. Cellular senescence in normal physiology. Science 384, 1300\u20131301 (2024).<\/p>\n Article<\/a>\u00a0 Achuthan, S., Santhoshkumar, T. R., Prabhakar, J., Nair, S. A. & Pillai, M. R. Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J. Biol. Chem. 286, 37813\u201337829 (2011).<\/p>\n Article<\/a>\u00a0 Paffenholz, S. V. et al. Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. Proc. Natl. Acad. Sci. USA 119, e2117754119 (2022).<\/p>\n Zhang, S. et al. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene 33, 116\u2013128 (2014).<\/p>\n Article<\/a>\u00a0 Harrington B. S., Annunziata C. M. NF-kappaB signaling in ovarian cancer. Cancers (Basel) 11, 1182 (2019).<\/p>\n Diepstraten, S. T. et al. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat. Rev. Cancer 22, 45\u201364 (2022).<\/p>\n Article<\/a>\u00a0 Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899\u2013905 (2010).<\/p>\n Article<\/a>\u00a0 Vogler, M. Targeting BCL2-proteins for the treatment of solid tumours. Adv. Med. 2014, 943648 (2014).<\/p>\n Article<\/a>\u00a0 Li, M., Wang, D., He, J., Chen, L. & Li, H. Bcl-X(L): a multifunctional anti-apoptotic protein. Pharmacol. Res. 151, 104547 (2020).<\/p>\n Article<\/a>\u00a0 Dai, H., Meng, X. W. & Kaufmann, S. H. Mitochondrial apoptosis and BH3 mimetics. F1000Res 5, 2804 (2016).<\/p>\n Article<\/a>\u00a0 Stover, E. H. et al. Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer. Mol. Cancer Res. 17, 2281\u20132293 (2019).<\/p>\n Article<\/a>\u00a0 Liu, D. et al. Constitutive BAK\/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer. Cell Death Dis. 12, 789 (2021).<\/p>\n Article<\/a>\u00a0 Yosef, R. et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun. 7, 11190 (2016).<\/p>\n Article<\/a>\u00a0 Witham, J. et al. The Bcl-2\/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin. Cancer Res. 13, 7191\u20137198 (2007).<\/p>\n Article<\/a>\u00a0 Chang, J. et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78\u201383 (2016).<\/p>\n Article<\/a>\u00a0 Bharti, V. et al. BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis. Cell Rep. 41, 111826 (2022).<\/p>\n Article<\/a>\u00a0 Hurley, R. M. et al. Characterization of a RAD51C-silenced high grade serous ovarian cancer model during development of PARP inhibitor resistance. NAR Cancer 3, zcab028 (2021).<\/p>\n Article<\/a>\u00a0 Zhang, X. et al. Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer. Sci. Adv. 9, eadf7195 (2023).<\/p>\n Article<\/a>\u00a0 Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123\u2013134 (2009).<\/p>\n Article<\/a>\u00a0 Martin, S. J. et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med 182, 1545\u20131556 (1995).<\/p>\n Article<\/a>\u00a0 Lee, S. H., Meng, X. W., Flatten, K. S., Loegering, D. A. & Kaufmann, S. H. Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm. Cell Death Differ. 20, 64\u201376 (2013).<\/p>\n Article<\/a>\u00a0 Kortmann, U. et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin. Cancer Res. 17, 783\u2013791 (2011).<\/p>\n Article<\/a>\u00a0 Patel, A. G., De Lorenzo, S. B., Flatten, K. S., Poirier, G. G. & Kaufmann, S. H. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin. Cancer Res. 18, 1655\u20131662 (2012).<\/p>\n Article<\/a>\u00a0 Goto, H. et al. Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J. Biol. Chem. 274, 25543\u201325549 (1999).<\/p>\n Article<\/a>\u00a0 Sakai, W. et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 69, 6381\u20136386 (2009).<\/p>\n Article<\/a>\u00a0 McGehee, C. D. et al. Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistance. Nucleic Acids Res. 53, gkaf990 (2025).<\/p>\n Antolin, A. A. et al. The kinase polypharmacology landscape of clinical PARP inhibitors. Sci. Rep. 10, 2585 (2020).<\/p>\n Article<\/a>\u00a0 Knezevic, C. E. et al. Proteome-wide profiling of clinical PARP inhibitors reveals compound-specific secondary targets. Cell Chem. Biol. 23, 1490\u20131503 (2016).<\/p>\n Article<\/a>\u00a0 Cardenas, C. et al. Adipocyte microenvironment promotes Bcl(xl) expression and confers chemoresistance in ovarian cancer cells. Apoptosis 22, 558\u2013569 (2017).<\/p>\n Article<\/a>\u00a0 Venkatachalam, A. et al. Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors. Mol. Cancer 23, 224 (2024).<\/p>\n Article<\/a>\u00a0 da Costa, A., Chowdhury, D., Shapiro, G. I., D\u2019Andrea, A. D., Konstantinopoulos, P. A. Targeting replication stress in cancer therapy. Nat. Rev. Drug Discov. 22, 38\u201358 (2022).<\/p>\n Leverson, J. D. et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci. Transl. Med. 7, 279ra240 (2015).<\/p>\n Article<\/a>\u00a0 Al, H. illiM. M. et al. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecol. Oncol. 143, 379\u2013388 (2016).<\/p>\n Article<\/a>\u00a0 DiSilvestro, P. et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J. Clin. Oncol. 41, 609\u2013617 (2023).<\/p>\n Article<\/a>\u00a0 Monk, B. J. et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann. Oncol. 35, 981\u2013992 (2024).<\/p>\n Article<\/a>\u00a0 Cecere, S. C. et al. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome. Gynecol. Oncol. 156, 38\u201344 (2020).<\/p>\n Article<\/a>\u00a0 Hurley, R. M. et al. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecol. Oncol. 153, 127\u2013134 (2019).<\/p>\n Article<\/a>\u00a0 Lord, C. J. & Ashworth, A. PARP inhibitors: Synthetic lethality in the clinic. Science 355, 1152\u20131158 (2017).<\/p>\n Article<\/a>\u00a0 Lheureux, S. et al. EVOLVE: A multicenter open-label single-arm clinical and translational phase II Trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression. Clin. Cancer Res. 26, 4206\u20134215 (2020).<\/p>\n Article<\/a>\u00a0 Swisher, E. M. et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat. Commun. 12, 2487 (2021).<\/p>\n Article<\/a>\u00a0 Collet, L. et al. BRCA1\/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges. Front Oncol. 14, 1354427 (2024).<\/p>\n Article<\/a>\u00a0 Puthalakath, H., Huang, D. C. S., O\u2019Reilly, L. A., King, S. M. & Strasser, A. The proapoptotic activity of the Bcl-2 family member bim is regulated by interaction with the dynein motor complex. Mol. Cell 3, 287\u2013296 (1999).<\/p>\n Article<\/a>\u00a0 Montero, J. et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 160, 977\u2013989 (2015).<\/p>\n Article<\/a>\u00a0 Rodman, E. P. B. et al. Lestaurtinib\u2019s antineoplastic activity converges on JAK\/STAT signaling to inhibit treatment naive and therapy resistant forms ovarian cancer. npj Precis. Oncol. 9, 236 (2025).<\/p>\n Article<\/a>\u00a0 Kaufmann, S. H. et al. Altered Formation of Topotecan-Stabilized Topoisomerase I-DNA Adducts in Human Leukemia Cells. Blood 89, 2098\u20132104 (1997).<\/p>\n Article<\/a>\u00a0 Kaufmann, S. H. Reutilization of Immunoblots After Chemiluminescent Detection. Anal. Biochem 296, 283\u2013286 (2001).<\/p>\n Article<\/a>\u00a0 Dai, H. et al. Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. Genes Dev. 29, 2140\u20132152 (2015).<\/p>\n Article<\/a>\u00a0 Cliby, W. A., Lewis, K. A., Lilly, K. K. & Kaufmann, S. H. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J. Biol. Chem. 277, 1599\u20131606 (2002).<\/p>\n Article<\/a>\u00a0 Chou, T.-C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Reg. 22, 27\u201355 (1984).<\/p>\n Article<\/a>\u00a0 Berenbaum, M. C. What is Synergy? Pharmacol. Rev. 41, 93\u2013141 (1989).<\/p>\n Article<\/a>\u00a0 Weroha, S. J. et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin. Cancer Res. 20, 1288\u20131297 (2014).<\/p>\n Article<\/a>\u00a0 Oberg, A. L. et al. Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting. Sci. Rep. 11, 8076 (2021).<\/p>\n Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n","protected":false},"excerpt":{"rendered":"Kaufman, B. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J. Clin.…\n","protected":false},"author":2,"featured_media":606664,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[6472,5300,14819,2294,298884,3536,14214,111,139,69,6840,6842,298885,145],"class_list":["post-606663","post","type-post","status-publish","format-standard","has-post-thumbnail","category-technology","tag-cancer-research","tag-cell-biology","tag-drug-development","tag-general","tag-gynaecological-cancer","tag-internal-medicine","tag-medicine-public-health","tag-new-zealand","tag-newzealand","tag-nz","tag-oncology","tag-pathology","tag-senescence","tag-technology"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/606663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=606663"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/606663\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/606664"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=606663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=606663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=606663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}